Questions to ask before agreeing to peptide treatment

Start with the active ingredient, brand or product name, formulation, route, and intended condition. “Peptide therapy” is too broad to consent to. Ask whether the product is FDA-approved for that use, an approved medicine proposed off label, a lawfully compounded drug, or an investigational product in a trial. FDA distinguishes these categories because each has different evidence and oversight. A clinician should be able to state the proposed category clearly, without relying on phrases such as “medical grade.” FDA: Understanding FDA terms

Ask which human studies support the exact use, how many participants were studied, what outcomes improved, and what important uncertainties remain. If the evidence involves only cells or animals, ask why a patient benefit is expected despite the gap. MedlinePlus notes that randomized clinical trials provide the clearest information about whether an intervention works in humans. Evidence for a different drug, route, or indication should be identified as indirect. MedlinePlus: Understanding medical research

Discuss common adverse effects, serious warning signs, drug interactions, pregnancy considerations, and what to do if a problem occurs. Ask what happens if you decline treatment or use an established alternative. AHRQ’s medicine checklist encourages questions about what a drug is for, how to recognize benefit, and when to contact the clinician. Consent should leave room to say no or take time to decide. AHRQ: Questions before taking medicine

Obtain the dispensing pharmacy name and verify its license where you live. Ask whether the prescriber will review follow-up information and whether you can reach a pharmacist. For a compounded drug, ask why an approved option cannot meet the identified need; FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Also request a complete written price, including visits, tests, medicines, shipping, and cancellation terms. FDA: Compounding and the FDA Q&A

Write the answers in five lines: What condition are we treating? What exact product and regulatory status? Which human study supports this use? What serious or common harms matter to me? Who do I contact if something goes wrong? If the clinician cannot answer one line, ask whether more evaluation is needed. A clear explanation should be possible without an elaborate sales presentation. AHRQ: Questions before taking medicine

The clinician may say the evidence is strong for one approved use, limited for an off-label use, or absent for a marketed research molecule. That distinction is useful even when it makes the decision harder. Consent should also address what happens without the proposed treatment and how uncertainty will be monitored. A request for time to review a label or study is reasonable for a nonurgent decision. FDA: Understanding off-label use